Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 12, 2004, Pages 4513-4519

  Pammit, Michael A ^a   Budhavarapu, Varija N ^a   Raulie, Erin K ^a   Klose, Karl E ^a   Teale, Judy M ^b   Arulanandam, Bernard P ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; GENTAMICIN; INTERLEUKIN 12;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FRANCISELLA TULARENSIS; LETHALITY; LUNG INFECTION; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TULAREMIA;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTI-BACTERIAL AGENTS; FEMALE; FRANCISELLA TULARENSIS; GENTAMICINS; INTERFERON TYPE II; INTERLEUKIN-12; LUNG; MICE; MICE, INBRED BALB C; PHAGOCYTOSIS; SURVIVAL ANALYSIS; TULAREMIA;

EID: 9644307958     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.12.4513-4519.2004     Document Type: Article

References (46)

1. Arulanandam, B. P., J. M. Lynch, D. E. Briles, S. Hollingshead, and D. W. Metzger. 2001. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect. Immun. 69:6718-6724.
2. Arulanandam, B. P., M. O'Toole, and D. W. Metzger. 1999. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J. Infect. Dis. 180:940-949.
3. Arulanandam, B. P., R. H. Raeder, J. G. Nedrud, D. J. Bucher, J. Le, and D. W. Metzger. 2001. IgA immunodeficiency leads to inadequate Th cell priming and increased susceptibility to influenza virus infection. J. Immunol. 166:226-231.
4. Brookmeyer, R., and N. Blades. 2002. Prevention of inhalational anthrax in the U.S. outbreak. Science 295:1861.
5. Christopher, G. W., T. J. Cieslak, J. A. Pavlin, and E. M. Eitzen, Jr. 1997. Biological warfare. A historical perspective. JAMA 278:412-417.
6. Clemons, K. V., E. Brummer, and D. A. Stevens. 1994. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob. Agents Chemother. 38:460-464.
7. Dennis, D. T., T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, A. M. Friedlander, J. Hauer, M. Layton, S. R. Lillibridge, J. E. McDade, M. T. Osterholm, T. O'Toole, G. Parker, T. M. Perl, P. K. Russell, and K. Tonat. 2001. Tularemia as a biological weapon: medical and public health management. JAMA 285:2763-2773.
8. Doherty, T. M., and A. Sher. 1998. IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J. Immunol. 160:5428-5435.
9. Donowitz, G. R. 1994. Tissue-directed antibiotics and intracellular parasites: complex interaction of phagocytes, pathogens, and drugs. Clin. Infect. Dis. 19:926-930.
10. Elkins, K. L., A. Cooper, S. M. Colombini, S. C. Cowley, and T. L. Kieffer. 2002. In vivo clearance of an intracellular bacterium, Francisella tularensis LVS, is dependent on the p40 subunit of interleukin-12 (IL-12) but not on IL-12 p70. Infect. Immun. 70:1936-1948.
11. Ellis, J., P. C. Oyston, M. Green, and R. W. Titball. 2002. Tularemia. Clin. Microbiol. Rev. 15:631-646.
12. Enderlin, G., L. Morales, R. F. Jacobs, and J. T. Cross. 1994. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin. Infect. Dis. 19:42-47.
13. Evans, M. E., D. W. Gregory, W. Schaffner, and Z. A. McGee. 1985. Tularemia: a 30-year experience with 88 cases. Medicine (Baltimore) 64:251-269.
14. Fan, P., F. Dong, Y. Huang, and G. Zhong. 2002. Chlamydia pneumoniae secretion of a protease-like activity factor for degrading host cell transcription factors required for major histocompatibility complex antigen expression. Infect. Immun. 70:345-349. (Erratum, 70:1664.)
15. Forsman, M., G. Sandstrom, and A. Sjostedt. 1994. Analysis of 16S ribosomal DNA sequences of Francisella strains and utilization for determination of the phylogeny of the genus and for identification of strains by PCR. Int. J. Syst. Bacteriol. 44:38-46.
16. Fortier, A. H., T. Polsinelli, S. J. Green, and C. A. Nacy. 1992. Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells, and effector molecules. Infect. Immun. 60:817-825.
17. Gately, M. K., U. Gubler, M. J. Brunda, R. R. Nadeau, T. D. Anderson, J. M. Lipman, and U. Sarmiento. 1994. Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases. Ther. Immunol. 1:187-196.
18. Harris, S. 1992. Japanese biological warfare research on humans: a case study of microbiology and ethics. Ann. N. Y. Acad. Sci. 666:21-52.
19. Havell, E. A. 1992. Role of TNF in resistance to bacteria. Immunol. Ser. 56:341-363.
20. Huber, V. C., B. P. Arulanandam, P. M. Arnaboldi, M. K. Elmore, C. E. Sheehan, B. V. Kallakury, and D. W. Metzger. 2003. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int. Immunopharmacol. 3:801-309.
21. Johansson, A., L. Berglund, L. Gothefors, A. Sjostedt, and A. Tarnvik. 2000. Ciprofloxacin for treatment of tularemia in children. Pediatr. Infect. Dis. J. 19:449-453.
22. Johnson, J. D., W. L. Hand, J. B. Francis, N. King-Thompson, and R. W. Corwin. 1980. Antibiotic uptake by alveolar macrophages. J. Lab. Clin. Med. 95:429-439.
23. Limaye, A. P., and C. J. Hooper. 1999. Treatment of tularemia with fluoroquinolones: two cases and review. Clin. Infect. Dis. 29:922-924.
24. Marinaro, M., P. N. Boyaka, R. J. Jackson, F. D. Finkelman, H. Kiyono, E. Jirillo, and J. R. McGhee. 1999. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin. J. Immunol. 162:114-121.
25. Mason, W. L., H. T. Eigelsbach, S. F. Little, and J. H. Bates. 1980. Treatment of tularemia, including pulmonary tularemia, with gentamicin. Am. Rev. Respir. Dis. 121:39-45.
26. Matsushita, T., K. Ando, K. Kimura, H. Ohnishi, M. Imawari, Y. Muto, and H. Moriwaki. 1999. IL-12 induces specific cytotoxicity against regenerating hepatocytes in vivo. Int. Immunol. 11:657-665.
27. Maurin, M., N. F. Mersall, and D. Raoult. 2000. Bactericidal activities of antibiotics against intracellular Francisella tularensis. Antimicrob. Agents Chemother. 44:3428-3431.
28. Maurin, M., and D. Raoult. 1996. Optimum treatment of intracellular infection. Drugs 52:45-59.
29. McMurray, D. N. 2001. Disease model: pulmonary tuberculosis. Trends Mol. Med. 7:135-137.
30. Munder, M., M. Mallo, K. Eichmann, and M. Modolell. 1998. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J. Exp. Med. 187:2103-2108.
31. Okada, E., S. Sasaki, N. Ishii, I. Aoki, T. Yasuda, K. Nishioka, J. Fukushima, J. Miyazaki, B. Wahren, and K. Okuda. 1997. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J. Immunol. 159:3638-3647.
32. Onyeji, C. O., K. Q. Bui, D. P. Nicolau, C. H. Nightingale, L. Bow, and R. Quintiliani. 1999. Influence of adjunctive interferon-gamma on treatment of gentamicin- and vancomycin-resistant Enterococcus faecalis infection in mice. Int. J. Antimicrob. Agents 12:301-309.
33. Onyeji, C. O., D. P. Nicolau, C. H. Nightingale, and L. Bow. 1999. Interferon-gamma effects on activities of gentamicin and vancomycin against Enterococcus faecalis resistant to the drugs: an in vitro study with human neutrophils. Int. S. Antimicrob. Agents 11:31-37.
34. Ouadrhiri, Y., and Y. Sibille. 2000. Phagocytosis and killing of intracellular pathogens: interaction between cytokines and antibiotics. Curr. Opin. Infect. Dis. 13:233-240.
35. Russell, P., S. M. Eley, M. J. Fulop, D. L. Bell, and R. W. Titball. 1998. The efficacy of ciprofloxacin and doxycycline against experimental tularaemia. J. Antimicrob. Chemother. 41:461-465.
36. Sawyer, W. D., H. G. Dangerfield, A. L. Hogge, and D. Crozier. 1966. Antibiotic prophylaxis and therapy of airborne tularemia. Bacteriol. Rev. 30:542-550.
37. Stevens, D. A. 1998. Combination immunotherapy and antifungal chemotherapy. Clin. Infect. Dis. 26:1266-1269.
38. Syrjala, H., R. Schildt, and S. Raisainen. 1991. In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 10:68-70.
39. Tarnvik, A. 1989. Nature of protective immunity to Francisella tularensis. Rev. Infect. Dis. 11:440-451.
40. Taylor, A. P., and H. W. Murray. 1997. Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice. J. Exp. Med. 185:1231-1239.
41. Titball, R. W., A. Johansson, and M. Forsman. 2003. Will the enigma of Frandsella tularensis virulence soon be solved? Trends Microbiol. 11:118-123.
42. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:133-146.
43. van de Vosse, E., E. G. Lichtenauer-Kaligis, J. T. van Dissel, and T. H. Ottenhoff. 2003. Genetic variations in the interleukin-12/interleukin-23 receptor (beta1) chain, and implications for IL-12 and IL-23 receptor structure and function. Immunogenetics 54:817-829.
44. Wolf, J. E., and S. E. Massof. 1990. In vivo activation of macrophage oxidative burst activity by cytokines and amphotericin B. Infect. Immun. 58:1296-1300.
45. Wong, J. P., H. Yang, K. L. Blasetti, G. Schnell, J. Conley, and L. N. Schofield. 2003. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J. Control. Release 92:265-273.
46. Zhong, G., T. Fan, and L. Liu. 1999. Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. J. Exp. Med. 189:1931-1938.